Moving Medicine Forward

CTI Clinical Trial and Consulting Services presents Moving Medicine Forward, a podcast centered on advancements in healthcare and elevating individual’s stories and expertise. CTI, a global Contract Research organization with associates in 60 countries, has contributed to 10,000+ projects, 200+ drug and device approvals, and 300+ pharmaceutical and emerging biotechnology partners. Our group of innovative thinkers work to change the lives of chronically and critically ill patients.

Moving Medicine Forward is a science podcast hosted by CTI Clinical Trials, with 68 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

CTI Clinical Trials hosts Moving Medicine Forward, a science show with 68 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #68

  Chill, Not Kill: How Quell Therapeutics is Reimagining Cell Therapy

  Aug 14, 202623 minS1

  In this episode of Moving Medicine Forward , Jeremy Schrand is joined by Luke Devey, Chief Medical Officer at Quell Therapeutics, and Savannah Doliboa, Chief Commercial Officer at CTI, to discuss how engineered regulatory T cell therapies are being developed to “chill, not kill” the immune system. The conversation explores Quell Therapeutics’ approach to Treg cell therapy, the complexity of launching advanced cell therapy trials across Europe, and how strong collaboration helped accelerate study startup for patients with serious autoimmune diseases. 00:00 Introduction to Quell Therapeutics and its "Chill, Not Kill" approach to engineered Treg cell therapies 01:13 What engineered regulatory T cells are and how they differ from traditional CAR-T therapies 02:31 Launching a first-in-human basket trial in rheumatoid arthritis and systemic sclerosis with CTI 03:05 Why Quell selected the UK, Germany, and Spain for study startup and site activation 05:27 Finding the right CRO partner: Why Quell chose CTI Clinical Trial and Consulting Services 07:21 Navigating regulatory pathways, site readiness, and operational complexity in advanced cell therapy trials 10:47 The strategy behind accelerating study startup and overcoming traditional delays 12:05 Achieving first-patient-ready status in 113 days, cutting benchmark timelines by 48% 13:57 The patient impact: addressing significant unmet needs in rheumatoid arthritis and systemic sclerosis 17:00 Key lessons from the trial and building a culture focused on collaboration, innovation, and patient outcomes 20:58 What's next for Quell Therapeutics and the future of engineered Treg cell therapies

  ListenShow Notes
• 

  Episode #67

  Beyond the Fine Print: How Legal Affairs Enables Clinical Research

  Aug 5, 202621 minS1

  Ian Hennessey, Vice President & General Counsel at CTI, joins Moving Medicine Forward to discuss the critical role legal affairs plays in advancing global clinical research. From navigating complex regulations and supporting trial operations to evaluating emerging technologies like AI, Ian shares how legal teams help organizations innovate responsibly while protecting patients and empowering scientific progress 00:00 | Career Journey From healthcare law to clinical research. 02:41 | Leadership & Mentorship Building teams through trust, support, and shared problem-solving. 04:11 | Global Research Challenges Navigating regulations across countries while advancing clinical trials. 05:38 | Legal Affairs at CTI How legal operations, contracting, and compliance support research success. 07:31 | Enabling Innovation Balancing business goals, risk, and compliance with a solutions-first mindset. 08:50 | Adapting to Change Managing evolving regulations, technology, and industry expectations. 12:23 | AI and Clinical Research Exploring the opportunities and risks of emerging technologies. 15:41 | Looking Ahead Why the future of clinical research remains so promising. 17:31 | Career Advice Guidance for professionals considering a career in life sciences legal affairs.

  ListenShow Notes
• 

  Episode #65

  Building Better Clinical Trials: Study Start-Up, Patients, and Global Data

  Jul 23, 202623 minS1

  What does it take to set a complex global clinical trial up for success? In this episode of Moving Medicine Forward , we are joined by Megan Kamm, Senior Vice President of Client Delivery, and Josh Schroeder, Vice President of Site & Field Operations, to discuss how strong planning, site partnerships, and cross-functional collaboration drive successful trial execution. From feasibility and study startup to patient centered decision-making, biometrics strategy, and global expansion, they share insights into the operational challenge —and opportunities—behind bringing innovative therapies to patients faster. 01:22 Megan Kamm and Josh Schroeder discuss their expanded leadership roles and growing collaboration across teams. 03:44 Why feasibility, country strategy, and study startup are critical to trial success. 05:07 The importance of site partnerships, patient experience, and reducing operational burden. 06:16 How project managers, CRAs, data managers, and site teams work together to execute complex trials. 07:01 Common startup challenges and strategies for keeping studies on track. 08:13 Managing patient-centered logistics in rare disease and cell & gene therapy programs. 11:15 Real-world examples of strong coordination improving enrollment and accelerating timelines. 13:19 The growing role of biometrics, statistics, and risk-based monitoring in study execution. 15:15 Scaling global teams through consistent training, leadership alignment, and operational excellence. 16:48 What differentiates CTI: collaboration, service, and a deep commitment to patients. 18:59 Looking ahead: AI, technology, startup optimization, and continued global growth. 21:05 Opportunities and challenges of expanding operations in China and the APAC region.

  ListenShow Notes
• 

  Episode #63

  From Australia to China: CTI's APAC Growth Journey

  Jul 15, 202613 minS1

  Asia Pacific has become one of the fastest-growing regions in clinical research, offering sponsors new opportunities to advance clinical development in an increasingly complex global environment. In this episode, Pavels Anetko, Director of Clinical Operations and Clinical Project Management at CTI, shares insights from across the region, including Australia's strengths in early phase studies and CTI's recent expansion into China and Japan. 01:24 Pavels’ background, career journey, and leadership role overseeing CTI's project management teams across Asia Pacific. 02:13 Why APAC is one of the fastest-growing regions for clinical development and the increasing influence of China. 02:41 CTI's growth strategy in Australia and the region's advantages for early-phase research, including the CTN regulatory pathway and R&D tax incentives. 04:06 The rise of healthy volunteer and Phase I studies in Australia. 04:27 Building CTI's presence in China and Japan and navigating more complex regulatory environments. 05:05 Staying aligned with regional regulatory requirements while maintaining global clinical trial standards. 05:40 How CTI helps sponsors select the right countries, sites, and patient populations across APAC. 06:20 Why local infrastructure, language expertise, and in-country teams are critical to trial success. 07:09 Challenges sponsors face when entering new APAC markets and how local support reduces risk. 07:36 The strategic value of including Japan and China in global studies, including access to patients and regulatory considerations. 08:58 How APAC can accelerate development timelines and strengthen regulatory submissions. 09:38 Key operational considerations for global studies, including logistics, specimen handling, and country-specific requirements. 10:08 Emerging opportunities across APAC, including growth in Southeast Asia and expanding clinical research markets. 10:54 Pavels shares career highlights, including gene therapy studies in Australia and supporting COVID-19 vaccine trials in Singapore. 12:44 Closing thoughts on the future of APAC and its growing influence on global clinical development.

  ListenShow Notes
• 

  Episode #63

  ALK Positive: How Patients are Driving Research

  Jul 8, 202639 minS1

  Summer Farmen and Jeff Sturm share their personal cancer journeys and the mission behind ALK Positive, CTI’s Q3 Charity of the Quarter. ALK Positive is a patient-driven organization dedicated to improving outcomes for individuals living with ALK-positive cancer. Together, they discuss how they became advocates within a global patient community, the importance of genetic testing and second opinions, and the role of research initiatives and clinical trials in advancing treatment options and improving patient outcomes. 00:00 Introduction to ALK Positive and today's guests, Summer Farmen and Jeff Sturm. 01:14 Summer and Jeff share their personal cancer journeys and what led them to become advocates within the ALK Positive community. 02:33 The mission of ALK Positive: connecting patients, funding research, and ensuring no one faces the diagnosis alone. 03:49 Why second opinions matter and how specialized expertise can significantly impact treatment decisions. 06:19 Research initiatives supported by ALK Positive, including clinical trials, grants, and collaborations focused on new treatment approaches. 10:46 Challenging the perception of ALK-positive cancer as a “rare” disease and advocating for greater representation in research and clinical trials. 13:22 How targeted therapies have transformed outcomes and extended survival for many ALK-positive patients. 15:47 The realities of survivorship: managing side effects, quality of life, and the role of palliative care. 17:27 The importance of genetic testing, monitoring disease progression, and making informed treatment decisions. 21:15 Clinical trial participation: common barriers, improving access, and helping patients connect with opportunities. 26:16 Building community through support groups, education programs, Healing Arts initiatives, and patient connections. 28:46 Addressing the emotional and mental health challenges that often accompany a cancer diagnosis. 32:50 Looking ahead: emerging therapies, vaccine research, precision medicine, and the future of ALK-positive cancer treatment. 36:51 Resources available through ALK Positive and how patients and caregivers can get involved. 37:54 Closing thoughts on advocacy, community, and the patient voices helping shape the future of cancer research.

  ListenShow Notes

Recent guests on Moving Medicine Forward. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.